Clinical Trial Update: The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating grazoprevir and elbasvir in participants with renal impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Renal Impairment

Drugs mentioned

• Elbasvir (elbasvir)
• Grazoprevir (grazoprevir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C, Renal Impairment | Phase 1 | Status: COMPLETED | Results posted: 2016-03-04